The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective

Abstract

The use of stem-cell therapies for the treatment of various musculoskeletal conditions, especially knee osteoarthritis (OA), is rapidly expanding, despite only low-level evidence to support its use. Centers offering these therapies are often marketing and charging patients out-of-pocket costs for such services. Therefore, the purpose of this study was to determine the current marketed: (1) prices and (2) clinical efficacy of stem-cell therapies for knee OA. This was a prospective cross-sectional study which queried 317 U.S. centers that offered direct-to-consumer stem-cell therapies for musculoskeletal conditions. A total of 273 of 317 centers were successfully contacted via phone or e-mail, using a simulated 57-year-old male patient with knee OA. Scripted questions were asked by the simulated patient to determine the marketed prices and clinical efficacy. Centers generally reported the proportion of patients who had “good results” or “symptomatic improvement.” The mean price of a unilateral (same-day) stem-cell knee injection was $5,156 with a standard deviation of $2,446 (95% confidence interval [CI]: $4,550–5,762, n = 65). The mean proportion of claimed clinical efficacy was 82% with a standard deviation of 9.6% (95% CI: 79.0–85.5%, n = 36). Most American stem-cell centers offer therapies for knee OA. The cost of these therapies averages about $5,000 per injection, and centers claim that 80% of the patients had “good results” or “symptomatic improvement,” denoting a gap between what is documented in the published literature and the marketing claims. These findings offer both patients and physicians insight into the current stem-cell market for knee OA. We hope that with this information, providers can more optimally make patients aware of discrepancies between what is being marketed versus the current evidence-based landscape of these therapies for knee OA.

Keywords

knee - osteoarthritis - stem cells - cell-based therapies

^* The authors Nicolas S. Piuzzi and Mitchell Ng contributed equally to this work.

• References

• 1 Bauer TW. Stem cell therapy for knee pain-what exactly are we injecting, and why?. J Bone Joint Surg Am 2016; 98 (18) 1509-1510
• 2 Turner L, Knoepfler P. Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell 2016; 19 (02) 154-157
• 3 Qin J, Theis KA, Barbour KE, Helmick CG, Baker NA, Brady TJ. ; Centers for Disease Control and Prevention (CDC). Impact of arthritis and multiple chronic conditions on selected life domains - United States, 2013. Morb Mortal Wkly Rep 2015; 64 (21) 578-582
• 4 Bitton R. The economic burden of osteoarthritis. Am J Manag Care 2009; 15 (8, Suppl): S230-S235
• 5 Chahla J, Piuzzi NS, Mitchell JJ. , et al. Intra-articular cellular therapy for osteoarthritis and focal cartilage defect of the knee. J Bone Jt Surg 2016; 98: 1511-1521
• 6 Papakostidis C, Tosounidis TH, Jones E, Giannoudis PV. The role of “cell therapy” in osteonecrosis of the femoral head. A systematic review of the literature and meta-analysis of 7 studies. Acta Orthop 2016; 87 (01) 72-78
• 7 Khashan M, Inoue S, Berven SH. Cell based therapies as compared to autologous bone grafts for spinal arthrodesis. Spine 2013; 38 (21) 1885-1891
• 8 Srivastava A, Mason C, Wagena E. , et al. Part 1: defining unproven cellular therapies. Cytotherapy 2016; 18 (01) 117-119
• 9 George B. Regulations and guidelines governing stem cell based products: clinical considerations. Perspect Clin Res 2011; 2 (03) 94-99
• 10 Eldridge P, Griffin D, Janssen W, O’Donnell L. Part 3: understanding the manufacturing of unproven cellular therapy products. Cytotherapy 2016; 18 (01) 124-126
• 11 Nichols K, Janssen W, Wall D, Cuende N, Griffin D. Part 4: interaction between unproven cellular therapies and global medicinal product approval regulatory frameworks. Cytotherapy 2016; 18 (01) 127-137
• 12 Deans RJ, Gunter KC, Dominici M, Forte M. Part 5: unproven cell therapies and the commercialization of cell-based products. Cytotherapy 2016; 18 (01) 138-142
• 13 O'Donnell L, Turner L, Levine AD. Part 6: the role of communication in better understanding unproven cellular therapies. Cytotherapy 2016; 18 (01) 143-148
• 14 Weiss DJ, Rasko JEJ, Cuende N. , et al. Part 2: making the “unproven” “proven”. Cytotherapy 2016; 18 (01) 120-123
• 15 Fink Jr DW. FDA regulation of stem cell-based products. Science 2009; 324 (5935): 1662-1663
• 16 Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med 2006; 355 (16) 1730-1735
• 17 Bayon Y, Vertès AA, Ronfard V. , et al. Turning regenerative medicine breakthrough ideas and innovations into commercial products. Tissue Eng Part B Rev 2015; 21 (06) 560-571
• 18 2015 - Irvine Stem Cell Treatment Center 12/30/15. Available at: https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2015/ucm479837.htm . Accessed June 1, 2017
• 19 LaPrade CM, James EW, LaPrade RF, Engebretsen L. How should we evaluate outcomes for use of biologics in the knee?. J Knee Surg 2015; 28 (01) 35-44
• 20 Mahalatchimy A. Reimbursement of cell-based regenerative therapy in the UK and France. Med Law Rev 2016; 24 (02) 234-258
• 21 Rémuzat C, Toumi M, Jørgensen J, Kefalas P. Market access pathways for cell therapies in France. J Mark Access Health Policy 2015; 3: 1-17
• 22 Shankar S, Tetreault MW, Jegier BJ, Andersson GB, Della Valle CJ. A cost comparison of unicompartmental and total knee arthroplasty. Knee 2016; 23 (06) 1016-1019